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ABSTRACT
Purpose: The Central Retinal Enrichment Supplementation Trials (CREST) aim to investigate the potential
impact of macular pigment (MP) enrichment, following supplementation with a formulation containing 10 mg
lutein (L), 2 mg zeaxanthin (Z) and 10 mg meso-zeaxanthin (MZ), on visual function in normal subjects (Trial 1)
and in subjects with early age-related macular degeneration (AMD; Trial 2).
Methods: CREST is a single center, double-blind, randomized clinical trial. Trial 1 (12-month follow-up) subjects
are randomly assigned to a formulation containing 10 mg L, 10 mg MZ and 2 mg Z (n = 60) or placebo (n = 60).
Trial 2 (24-month follow-up) subjects are randomly assigned to a formulation containing 10 mg L, 10 mg MZ,
2 mg Z plus 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc and 2 mg copper (Intervention A; n = 75) or 10 mg L
and 2 mg Z plus 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc and 2 mg copper (Intervention B; n = 75).
Contrast sensitivity (CS) at 6 cycles per degree represents the primary outcome measure in each trial. Secondary
outcomes include: CS at other spatial frequencies, MP, best-corrected visual acuity, glare disability, photostress
recovery, light scatter, cognitive function, foveal architecture, serum carotenoid concentrations, and subjective
visual function. For Trial 2, AMD morphology, reading speed and reading acuity are also being recorded.
Conclusions: CREST is the first study to investigate the impact of supplementation with all three macular
carotenoids in the context of a large, double-blind, randomized clinical trial.
Keywords: Age-related macular degeneration, lutein, macular pigment, meso-zeaxanthin, randomized clinical
trial, visual performance, zeaxanthin
INTRODUCTION
A yellow pigment composed of the carotenoids lutein
(L), zeaxanthin (Z), and meso-zeaxanthin (MZ),1 accu-
mulates at the macula where it is known as macular
pigment (MP). MP is a short-wavelength (blue) light
filter2 and a powerful antioxidant,3 and is therefore
believed to protect against age-related macular degen-
eration (AMD),4 which is the commonest cause of
blindness in the developed world.5 In addition, MP is
essential for optimal vision because of its optical
properties.6–8
In July 2011, the European Research Council (ERC)
awarded funding of E1,493,342 to support and con-
duct the Central Retinal Enrichment Supplementation
Trials (CREST). The CREST project is funded under
the ERC ‘‘Ideas’’ Framework 7 program. These trials
were designed to investigate the impact of supple-
mentation with a combined carotenoid formulation of
L, Z, and MZ on visual function in normal subjects
(Trial 1) and in subjects with early AMD (Trial 2).
A novel and important feature of the CREST trials
is the inclusion of MZ in the study intervention.
Recent data from our laboratory show that optimal
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enrichment of MP is dependent upon inclusion of MZ
(along with L and Z) in the supplement formula-
tion.7,9,10 MZ is believed to be particularly important
for the following reasons. First, MZ is the dominant
macular carotenoid at the foveal epicenter,8 and is
therefore ideally located to exert optimal antioxidant
activity and short-wavelength light filtration at the
central macula, the specialized part of the retina
responsible for color vision and high spatial reso-
lution.11 Second, it has been shown (in vitro) that the
antioxidant properties of the macular carotenoids
(L, Z, and MZ) are enhanced when all three caroten-
oids are present.12 Third, the absorbance spectrum
of MZ extends the range of pre-receptoral short-
wavelength (blue) light filtration, and its orientation
(compared to L) in the Henle fiber layer likely confers
beneficial effects related to light polarization at the
macula.13 Last, it has been shown that individuals at
increased risk of AMD (i.e. older subjects and cigar-
ette smokers) are more likely to display atypical and
undesirable central dips in their MP spatial profiles,14
and it has been shown that these central dips can only
be normalized when MZ is included in a study
intervention.9,15
A novel and distinctive feature of the CREST
trials is the variety of methods and outcome
measures selected to assess visual function in both
the normal and AMD populations under investiga-
tion. These methods, which are described fully
below, are appropriate and sensitive to detect
change in visual function, if present.16,17 Indeed,
previous clinical trials investigating the potential
impact of carotenoid supplementation on visual
function in normal subjects6 and in patients with
early AMD18 were limited by the outcome measures
(e.g. typically best-corrected visual acuity; BCVA)
and in terms of interventions used (i.e. an interven-
tion without MZ).
The study hypothesis of CREST is that MP will be
uniquely and best enriched using a supplement
formulation containing all three macular carotenoids,
and that enrichment of MP centrally, and across its
spatial profile, will enhance visual function via the
optical properties of this pigment, by reducing the
deleterious effects of chromatic aberration, light scat-
ter, and veiling luminance in normal subjects (non-
diseased retina, Trial 1, see below) and in patients
with early AMD (diseased retina, Trial 2, see below).
This article outlines the design and methodology of
the CREST trials.
MATERIALS AND METHODS
Management, Design and Registration
The management of CREST, including its research
team, supporting service providers, and research
collaborators is summarized in Figure 1. CREST is a
parallel group, double blind, randomized controlled
trial studying two populations of interest. Trial 1 is
investigating the impact of macular carotenoid
nutrition on visual function in normal subjects, and
Trial 2 is investigating the impact of macular
carotenoid nutrition on visual function in patients
with early AMD. These trials are registered on the
current controlled trials register (Trial 1:
ISRCTN68270512; Trial 2: ISRCTN13894787) and are
being conducted as a single center study at the
Macular Pigment Research Group (www.mprg.ie),
Vision Research Centre, Waterford Institute of
Technology, Ireland. Figures 2 and 3 show the
consolidated standards of reporting trials diagram,19
explaining the flow of subjects through Trial 1 and
Trial 2, respectively.
Ethical Assessment and Approval
All subjects are required to provide written informed
consent prior to enrolment into CREST. Ethical
approval for the study was granted by the Research
Ethics Committee of the Waterford Institute of
Technology, Waterford, Ireland, and the Ethics
Committee of the ERC. CREST adheres to the tenets
of the Declaration of Helsinki, and will follow the full
code of ethics with respect to subject recruitment,
subject testing and data protection.
Research Questions
Trial 1: Does supplementation with all three macular
carotenoids in a ratio (mg/day) of 10:10:2 (L:MZ:Z),
for 12 months, enhance visual function in normal
subjects (without retinal disease) when compared to
placebo?
Trial 2: Does supplementation with all three macu-
lar carotenoids in a ratio (mg/day) of 10:10:2 (L:MZ:Z)
plus 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc
and 2 mg copper for 24 months, enhance visual
function in patients with early AMD when compared
to 10:2 (L:Z) plus 500 mg vitamin C, 400 IU vitamin E,
25 mg zinc and 2 mg copper.
Primary Outcome Measure
Contrast sensitivity (CS) at 6 cycles per degree (cpd) is
the primary outcome measure in both trials.
Secondary Outcome Measures
Secondary outcome measures include CS at other
spatial frequencies, visual acuity, glare disability,
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photostress recovery, MP, light scatter, foveal archi-
tecture, serum carotenoid concentrations, subjective
visual function, and cognitive function. In Trial 2,
AMD morphology, reading acuity and reading speed
are also being assessed.
Randomization and Intervention
Block randomization is used to assign subjects to
intervention groups for both trials. The use of
blocking is designed to ensure that an equal number
g
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FIGURE 1. Structure of the Central Retinal Enrichment Supplementation Trials (CREST) management and collaboration.
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of subjects are assigned to intervention groups. The
random numbers were generated using Minitab 16
Statistical Software (Minitab Inc, State College, PA,
USA) and the blocks generated by one of the methods
described by Friedman and co-authors.20 The ran-
domization ratio is 1:1 with no stratification. The
randomization code list was generated by the study
statistician (JS) who has no contact with study subjects
Assessed for eligibility
Excluded
♦   Did not meet inclusion criteria
♦   Declined to participate
♦   Other reasons  
24-month follow-up (clinical assessment at
baseline, 6, 12, 18 and 24 months)
Allocated to intervention A (n = 75)
♦ Received allocated intervention (10 mg
 lutein, 10 mg meso-zeaxanthin, 2 mg
 zeaxanthin plus 500 mg vitamin C, 400 IU
 of vitamin E, 25 mg zinc and 2 mg copper)
24-month follow-up (clinical assessment at
baseline, 6, 12, 18 and 24 months)
Allocated to intervention B (n = 75)
♦ Received allocated intervention (10 mg
 lutein, 2 mg zeaxanthin plus 500 mg
 vitamin C, 400 IU of vitamin E, 25 mg zinc
 and 2 mg copper)
Allocaon
Follow-Up
Randomized (n = 150)
Enrollment
FIGURE 3. Central Retinal Enrichment Supplementation Trials (CREST) Trial 2 consolidated standards of reporting trials flow
diagram.
Assessed for eligibility  
Excluded   
♦ Did not meet inclusion criteria  
♦ Declined to participate  
♦ Other reasons  
12 month follow-up (Clinical assessment at 
baseline, three, six and 12 months) 
Allocated to intervention (n = 60) 
♦ Received allocated intervention (10mg 
Lutein, 10mg Meso-zeaxanthin, 2mg 
Zeaxanthin)
12 month follow-up (Clinical assessment at 
baseline, three, six and 12 months) 
Allocated to intervention (n = 60) 
♦ Received allocated intervention (placebo)
Allocation
Follow-Up
Randomized (n = 120) 
Enrolment
FIGURE 2. Central Retinal Enrichment Supplementation Trials (CREST) Trial 1 consolidated statement of reporting trials flow
diagram.
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and no access to data until study completion. Random
allocation is carried out by a pharmacist (CK) at
Whitfield Clinic, Waterford, who has no contact with
study subjects. The pharmacist tosses a coin to assign
subjects to intervention groups based on the random-
ization code list. Study researchers only receive a box
of tablets with subject identification label. The code is
revealed only at study completion.
The intervention for Trial 1 is a softgel capsule
containing 10 mg L, 10 mg MZ and 2 mg Z in a
sunflower oil suspension (commercially available as
MacushieldTM, provided by Macuvision Europe
Limited, Solihull, UK, and prepared by EuroCaps
Limited, Tredegar, South Wales, UK). The placebo is a
softgel capsule containing sunflower oil (provided by
EuroCaps Limited, Tredegar, South Wales, UK). Trial 1
subjects are instructed to take one capsule daily with a
meal. The intervention and placebo supplements are
identical in external appearance and therefore the two
treatments are indistinguishable from each other.
The interventions for Trial 2 consist of a softgel
capsule containing 10 mg L, 10 mg MZ and 2 mg Z in a
sunflower oil suspension plus two multivitamin
capsules each containing 250 mg vitamin C, 200 IU
vitamin E, 12.5 mg zinc, and 1 mg copper (provided
by Macuvision Europe Limited, Solihull, UK, pre-
pared by EuroCaps Limited, Tredegar, South Wales,
UK; Intervention A) or a softgel capsule containing
10 mg L, 2 mg Z in a sunflower oil suspension plus
two multivitamin capsules each containing 250 mg
vitamin C, 200 IU vitamin E, 12.5 mg zinc, and 1 mg
copper (provided by Macuvision Europe Limited,
Solihull, UK, prepared by EuroCaps Limited,
Tredegar, South Wales, UK; Intervention B). The
macular carotenoid capsules are also indistinguish-
able from each other in external appearance. Trial 2
subjects are instructed to take one macular carotenoid
capsule and two multivitamin capsules daily with a
meal.
Compliance
Frequent phone calls and reminder text messages are
sent to subjects to ensure compliance with consump-
tion of the study intervention. Capsule counting is
implemented at follow-up visits. In addition, compli-
ance will be assessed at the end of the study (after the
randomization code is broken) by analyzing serum
carotenoid concentrations using high performance
liquid chromatography (see method below).
Sample Size Calculations
The primary outcome measure in CREST is change in
CS at 6cpd over the course of the study: Y = CS2 – CS1,
where CS1 is CS at baseline, CS2 is CS at the end of the
study. The appropriate statistical test is the independ-
ent samples t-test, comparing the mean change in Y in
treatment groups.
Pilot studies were conducted to inform CREST with
respect to power and sample size (trial
ISRCTN81595685). From this pilot work, estimates of
standard deviation of CS, and the correlation between
CS pre- and post-intervention were available and
were used in the sample size calculations. There was
strong evidence from the pilot work of a positive
effect (i.e. improvement in mean CS) of treatment on
CS relative to placebo and therefore a one-tailed
rather than a two-tailed test was deemed more
appropriate for Trial 1. For Trial 2, since there was
no such evidence for the two treatment groups, a two-
tailed test was used.
Using a clinically significant effect size of 0.15
logarithm (log) CS units (an improvement of one line
on a Thomson logarithm of the minimum angle of
resolution, LogMAR, chart) and on standard assump-
tions (5% level of significance, 80% power, equal
group sizes), the required minimum sample size in
Trial 1 is 90 subjects (45 per treatment group) and Trial
2 is 112 (56 per treatment group).21
However, assuming a 25% dropout rate for both
trials, we decided on a total sample size of 120 for
Trial 1 and a total sample size of 150 for Trial 2.
Some power calculations for secondary outcome
variables were also performed based on 45 subjects
per group. These were based on Cohen’s suggested
classification22 of effect sizes:
(a) Interval variables (independent samples t-tests),
e.g. for comparing changes in MP in the two
groups, with 45 subjects in each group, there is
very high power (0.98) for detecting a large effect
size (0.8 standard deviations on Cohen’s defin-
ition) and close to acceptable power (0.76) for
detecting a medium effect size (0.5 standard
deviations). These power calculations, as with
those for the principal outcome measure, assume
a 5% level of significance and a one-tailed test.
(b) Categorical variables, e.g. comparing numbers (at
the end of the study) in terms of AMD severity
grade categories for intervention groups. The
power in this case depends on the dimensions
of the contingency table. If there are two rows in
the table (two intervention groups) and three
columns (e.g. mild, moderate, and severe AMD)
then the power is 0.99 for detecting a large effect
(W = 0.5 on Cohen’s definition) and 0.72 for
detecting a medium effect (W = 0.3). The W-
statistic, devised by Cohen,22 is derived from the
2 statistic used to test for independence in the
contingency table. We have assumed a 5% level of
significance.
In summary, for analysis of secondary outcome
variables, interval or categorical, the power of this
study is inadequate for small effect sizes by Cohen’s
CREST: RCT Design and Methodology 115
! 2014 The Author(s)
O
ph
th
al
m
ic
 E
pi
de
m
io
l D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
17
6.
12
.1
07
.1
39
 o
n 
03
/2
4/
14
Fo
r 
pe
rs
on
al
 u
se
 o
nl
y.
definition (e.g. 0.2 standard deviations for an interval
variable), but the power is adequate/strong for
medium/large effect sizes. The results for power
presented here were obtained from the PASS 2008
software (NCSS LLC, Kaysville, Utah, USA).23
Eligibility Criteria
Trial 1
Inclusion criteria for Trial 1 include: (1) 18 years or
older; (2) BCVA of 6/6 or better; (3) no more than five
diopters spherical equivalence of refraction; (4) no
previous consumption of supplements containing the
macular carotenoids (L, Z and/or MZ); (5) no ocular
pathology; and (6) MP at 0.25 degrees of eccentricity
less than 0.5 optical density units. A subject is
described as normal where he/she exhibits no
vision-related abnormalities following a comprehen-
sive battery of tests, including BCVA (better than or
equal to 6/6), fundus photography (scrutinized by a
retinal specialist), optical coherence tomography
(OCT; scrutinized by a retinal specialist), and a
general health questionnaire, with particular attention
directed towards the possibility of diabetes mellitus or
amblyopia.
Trial 2
Inclusion criteria for Trial 2 include: (1) early AMD in
at least one eye, based on the grading of a fundus
photograph from one (drusen absent or questionable
or small hard drusen present, total drusen area
5125 mm diameter, without retinal pigment abnorm-
alities) to eight (drusen 0.5 disc area, DA, with
retinal pigment epithelium depigmentation 350mm
to 50.5 DA or any drusen with 0.5 DA retinal
pigment epithelium depigmentation) on the Age-
Related Eye Disease Study (AREDS) severity scale;24
(2) BCVA of 6/12 or better; (3) no more than five
diopters spherical equivalence of refraction; (4) no
previous consumption of supplements containing the
macular carotenoids (L, Z and/or MZ); (5) no other
retinal pathology beyond AMD; and (6) no diabetes
mellitus.
Screening Visits to Assess and Confirm
Eligibility
For both trials, efforts are made to ensure that subjects
enrolled into the study meet the inclusion criteria.
This is achieved by conducting a screening visit
on all subjects prior to enrollment into either CREST
trial.
Trial 1
Subjects are recruited into this trial through an
organized advertising campaign. National and local
media were informed of the trial and many main-
stream Irish newspapers published the call for vol-
unteers. Radio and online adverts have also been
carried out. In addition, flyers have been developed
for distribution to the general public. Educational
events for general practitioners, optometrists and
ophthalmologists are held regularly to create aware-
ness of the trial and to solicit help with recruitment.
Interested subjects attend our Vision Research Centre
and an initial assessment is performed to determine if
the subject meets the eligibility criteria for inclusion.
Clinical examination consisting of ocular and medical
history, BCVA, MP measurement, OCT and fundus
photography is carried out. The screening visit is
conducted to confirm absence of ocular pathology and
to satisfy all other criteria for inclusion.
Trial 2
Subjects are recruited from hospitals in the Republic
of Ireland. This has been facilitated by raising aware-
ness of the trial at each hospital. Also, as above,
educational events for general practitioners, optom-
etrists and ophthalmologists are held regularly to
create awareness of the trial and to solicit help with
recruitment. Interested and potential volunteers are
invited to attend our Vision Research Centre for
assessment to confirm eligibility (with particular
emphasis placed on presence of early AMD). During
the screening visit, demographic information is col-
lected. This is followed by measurement of BCVA. In
addition, anterior and posterior segment examination
using the Haag-Streit BM 900 Slit lamp biomicroscope
(Haag-Streit AG, Switzerland) is carried out by a
consultant ophthalmologist with a special interest in
AMD (SB). Subjects who are deemed suitable follow-
ing the ophthalmological examination by SB then
have stereo fundus photographs taken. These stereo
fundus photographs are then sent to the Reading
Centre at Moorfields Eye Hospital, London, for
confirmation that the patient has early AMD. Only
patients who have such confirmation by the Reading
Centre are invited to participate in the study.
Study Visits
In Trial 1, study visits are conducted at baseline, 3
months, 6 months, and 12 months. At each visit,
subjects undergo a series of tests and procedures,
which are described in detail below. Table 1 summar-
izes the clinical procedures conducted in Trial 1 at
each study visit. The duration of a typical study visit
is approximately 120 minutes.
In Trial 2, study visits are conducted at baseline, 6
months, 12 months, 18 months and 24 months. Table 2
summarizes the clinical procedures conducted in Trial
2 at each study visit. A typical study visit in Trial 2
takes about 150 minutes.
116 K. O. Akuffo et al.
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Statistical Analysis
Baseline analysis
Placebo and intervention groups will be investigated
for statistically significant differences in outcome
measures, demographic variables etc, at baseline.
This will be done using standard statistical analyses,
e.g. independent sample t-tests for interval variables
and contingency table analysis for categorical vari-
ables. It is expected that the randomization process
will result in the intervention groups being statistic-
ally comparable. However, any between-group differ-
ences in variables, which are identified at baseline,
will be controlled for in subsequent analyses.
Analysis of changes over time
If there is no need to control for baseline differences
between placebo and intervention groups, then a
straightforward independent sample t-test will suffice
for the analysis of change over time in the primary
outcome measure (CS at 6cpd). However, linear
mixed models20 may also be used, to control (if
necessary) for baseline differences between groups
and to analyze data from multiple time points. The
principle of intention to treat25–27 will not, in general,
be followed (but will nevertheless be performed) in
the statistical analysis, but wherever intention to treat-
based analysis is found to yield substantially different
findings to the main analysis, such discrepancies will
be reported.
Most of the secondary outcome measures in this
study (contrast sensitivity at other frequencies, MP,
serum concentrations, etc) are also interval variables,
and will be analyzed using the same methods as for
CS at 6cpd. However, some outcome variables (in
particular, in Trial 2, change in AMD severity grade
TABLE 2. Central Retinal Enrichment Supplementation Trials (CREST) study procedures in Trial 2.
Study procedures Baseline 6 months 12 months 18 months 24 months
Demographic and lifestyle questionnaire 
NEI VFQ-25  
Dietary carotenoid screener  
Cognitive function assessment  
Visual acuity assessment     
Reading acuity     
Reading speed     
Letter contrast sensitivity     
Contrast sensitivity with functional vision analyzer     
Light scatter     
Photostress recovery     
MP measurement by customized heterochromatic flicker photometry     
MP measurement by dual-wave autofluorescence     
Optical coherence tomography     
Fundus photography     
Fundus grading  
Serum carotenoid analysis     
MP, macular pigment; NEI VFQ-25, 25-item National Eye Institute Visual Functioning Questionnaire
TABLE 1. Central Retinal Enrichment Supplementation Trials (CREST) study procedures in Trial 1.
Study procedures Baseline 3 months 6 months 12 months
Demographic and lifestyle questionnaire 
Subjective visual function questionnaire  
Dietary carotenoid screener  
Cognitive function assessment  
Visual acuity assessment    
Letter contrast sensitivity    
Contrast sensitivity with functional vision analyzer    
Light scatter    
Photostress recovery    
MP measurement by customized heterochromatic flicker photometry    
MP measurement by dual-wave autofluorescence    
Optical coherence tomography    
Fundus photography    
Serum carotenoid analysis    
MP, macular pigment
CREST: RCT Design and Methodology 117
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over time in the intervention groups), are ordinal
rather than interval variables, and therefore logistic
regression or contingency table analysis will be used.
Statistical significance will be set at the standard
p50.05 for all analyses. In order to reduce the risk of a
type II error, there will be no adjustment for multiple
comparisons, but this will be clearly stated when
reporting study findings.
Questionnaires
Demographic and Lifestyle Questionnaire
The demographic and lifestyle questionnaire obtains
the following details: contact details, ethnicity,
education, occupation, smoking habits (history and
frequency), alcohol intake (average consumption per
week, frequency), exercise (number of sessions per
week, duration of each session in minutes), light
exposure (time spent outdoors, use of protective
eyewear such as sunglasses, photochromic lenses),
body mass index, blood pressure, medical history, and
ocular medical history.
Subjective Visual Function Questionnaire
The subjective visual function questionnaire assesses
visual function based on responses to closed-ended
questions under four subscales, namely glare disabil-
ity, acuity/spatial vision, light/dark adaptation and
daily visual tasks. This questionnaire is administered
in only Trial 1. All questions must be answered
(forced-choice). In each of the four subscales, subjects
respond to questions in three tiers. First, subjects rate
their visual function in specified daily scenarios
(situational analysis) using a five-point Likert scale
(never, rarely, sometimes, often, always). Second,
subjects compare their visual function to friends and
family in a comparative analysis using a five-point
Likert scale (significantly better than others, margin-
ally better than others, equivalent to others, margin-
ally worse than others, significantly worse than
others). Last, subjects rate their overall visual per-
formance on a scale from zero (worst) to 10 (best)
known as subjective satisfaction score. Each tier
analysis is computed to give a score out of 100 for
each subscale. This questionnaire has been previously
described.6
National Eye Institute Visual Functioning
Questionnaire 25
Subjective visual function is assessed in Trial 2 using
the validated28,29 National Eye Institute Visual
Functioning Questionnaire 25.30
Dietary Carotenoid Screener
The dietary carotenoid screener is a simplified ques-
tionnaire which assesses the dietary intake of four
carotenoid-rich food substances (eggs, broccoli, corn
and dark green leafy vegetables). Subjects indicate
their serving size by ticking any of six categories
(51/week, 1/week, 2–3/week, 4–6/week, 1/day,
41/day) with respect to each of the food substances.
Responses are entered into a computer program
developed by Professor Elizabeth Johnson, Tufts
University, USA, which weighs responses based on
the frequency of food intake and the bioavailability of
L and Z within these food substances, and calculates a
dietary score. The dietary scores generated range from
0–75, and are further divided into three subgroups
(low intake, category 1, 0–15: 2 mg/day; medium
intake, category 2, 16–30: 3–13 mg/day; high intake,
category 3, 31–75: 413 mg/day). This method has
been used previously by our group.9,31
Cognitive Function Assessment
Cambridge Neuropsychological Test Automated
Battery32–34 (CANTAB, Cambridge Cognition,
Cambridge, UK) assesses cognition using a computer-
ized software program. A battery of tests consisting of
the motor screening task,35,36 verbal recognition
memory,37 attention switching task38,39 and the
paired associate learning40 is used. The CANTAB
protocol41 is followed in the administration of these
tests.
Best-corrected Visual Acuity
BCVA is measured with a computerized LogMAR
Early Treatment Diabetic Retinopathy Study (ETDRS)
test chart (Test Chart 2000 Xpert, Thomson Software
Solutions, Hatfield, UK) viewed at 4 m. The Sloan
ETDRS letterset is used for this test. At the first
incompletely read line, the letters of the line are
randomized three times using the testing software’s
randomization function and an average of three scores
is taken. BCVA is recorded in visual acuity rating.
Contrast Sensitivity
Letter Contrast Sensitivity
Letter CS is assessed using the computerized
LogMAR ETDRS test chart (Test Chart 2000 PRO,
Thomson Software Solutions) at five different spatial
frequencies (1.2, 2.4, 6.0, 9.6, 15.15cpd).42 The Sloan
optotypes are chosen and subjects are asked to read
the letters aloud while fixating on the chart at a
distance of 4 m. The letter set is randomized during
the test at each change of contrast. The percentage
contrast of letter optotypes is decreased in 0.15 log CS
steps until the lowest contrast value for which subjects
see at least three letters is reached. The test is then
repeated for the other spatial frequencies. Each letter
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has a nominal log CS value of 0.03. Missed letters at
any contrast level are noted. The resultant log CS
value for the subject at a particular spatial frequency
is calculated by adding any extra letter(s) and/or
subtracting missed letters from best log CS value
corresponding to the lowest percentage contrast.
Contrast Sensitivity with Functional Acuity Contrast
Test
The Optec Functional Vision Analyzer43 (Stereo
Optical Co, Inc, Chicago, IL, USA) uses the functional
acuity contrast test44,45 to assess contrast sensitivity at
five different spatial frequencies (1.5, 3, 6, 12, 18cpd).
A detailed description of the method has been
reported previously.6,46
Light Scatter
Using the compensation comparison method, the
C-Quant Straylight Meter (Oculus GmbH, Wetzler,
Germany)48–50 measures light scatter by objectively
determining the amount of intraocular straylight on
the retina. Straylight measurements are reported in
logarithmic form and judged reliable when standard
deviation is 0.08, and the reliability coefficient is 1.
Photostress Recovery
Photostress recovery time is measured by assessing
CS and investigating the impact of a light stress using
a 300 watt tungsten spotlight (ARRI 300 Plus lamp,
ARRI Lighting Solutions GmbH, Berlin, Germany)
with a low-pass glass dichroic filter. Subjects view the
lamp directly with the study eye (the other eye is
covered with an eye patch) at a distance of 1 m for 10
seconds while limiting blinking. After 10 seconds, the
lamp is extinguished and removed from the subject’s
field of view. A letter size of 6/24 (LogMAR 0.6) is
displayed on the LogMAR test chart (Test Chart 2000
PRO, Thomson Software Solutions), and viewed at
4 m. A CS value of 0.30 log units (i.e. two lines) above
the individual’s contrast threshold, is used. The time
taken for the subject’s eye to recover and see all five
letters on the chart after the 10-second exposure is
taken as the photostress recovery time.
Macular Pigment Measurement by
Customized Heterochromatic Flicker
Photometry
Using the Macular Densitometer (Macular Metrics
Corp, Providence, RI, USA),51,52 MP is measured by
customized heterochromatic flicker photometry. The
spatial profile of MP is assessed by measuring MP at
0.25, 0.5, and 1.75 of retinal eccentricity, with a
reference point at 7. A detailed description of the
protocol is reported elsewhere.53,54
Pupillary Dilation
Subjects’ pupils are dilated prior to performing stereo
fundus photography, OCTand MP measurement using
dual-wavelength autofluorescence. A drop each of
0.5% proxymetacaine hydrochloride, 2.5% phenyl-
ephrine hydrochloride, and 1% tropicamide is used.
Macular Pigment Measurement by Dual-
wavelength Autofluorescence
Using the Spectralis HRA + OCT MultiColor
(Heidelberg Engineering GmbH, Heidelberg,
Germany), MP is measured by dual-wavelength (488
nm and 518 nm) autofluorescence.55–57 Subject details
are input into the Heidelberg Eye Explorer (HEYEX
version 1.7.1.0) software. Assessment is performed
with the room lights off. The following acquisition
parameters are used: high speed scan resolution, two
seconds cyclic buffer size, internal fixation, 30 seconds
movie and manual brightness control. Alignment,
focus and illumination are first adjusted in infrared
mode. Once the image is evenly illuminated, the laser
mode is switched from infrared to blue plus green
laser light autofluorescence. Focus and illumination
are re-adjusted for optimal acquisition. A 30-second
movie of the macula is acquired for subsequent MP
analysis using the HEYEX software.
Optical Coherence Tomography
Using the Spectralis HRA + OCT MultiColor (software
version 5.6, Heidelberg Engineering GmbH),58 foveal
architecture is assessed using OCT. The device pro-
duces non-invasive retinal histological tomographs by
integrating spectral (Fourier) domain OCT technology
with confocal scanning laser ophthalmoscopy. The
following scan acquisition protocol is used for Trial 1:
compact volume scan (20  20) of the macular area,
97 B-scans each spaced 60 mm apart at high speed with
automatic real-time mean (ART) of 9/frame rate; cross
scan (20  20) at high resolution with an ART of
10/frame rate. The following scan acquisition protocol
is used for Trial 2: volume scan (20  20) of the macu-
lar area, 193 B-scans each spaced 30 mm apart at high
speed with ART of 9/frame rate; cross scan (20  20)
at high resolution with an ART of 10/frame rate.
Fundus Photography and Grading
All photography is performed by trained and certified
photographers. For subjects in Trial 1, standard color
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fundus photographs centered on the macula are taken
using the Zeiss Visucam 200 (Carl Zeiss Meditec AG,
Jena, Germany) at a 45 magnification setting. These
fundus photographs are reviewed by SB in order to
exclude any other ocular pathology.
For subjects in Trial 2, stereo color fundus photo-
graphs are taken using the Zeiss Visucam 200 (Carl
Zeiss Meditec AG) at a 45 magnification setting. The
stereo photography technique used is the modified 3-
standard stereoscopic fields (Field 1: optic disc, Field
2: macula, Field 3: temporal to macula). In addition,
fundus reflex photographs of the external eye are
taken in order to document any media opacities. The
anonymized photographs are then sent for grading at
the Reading Centre, Moorfields Eye Hospital, London,
UK, using a secure file transfer protocol. Fundus
grading follows the AREDS 11-step severity scale.24
Reading Acuity and Reading Speed
This test is only being performed in Trial 2. Reading
acuity and reading speed are assessed with the
English version of the standardized Radner reading
chart59 at 40 cm. Reading acuity is recorded in loga-
rithm of the reading acuity determination (LogRAD).
Reading speed (the time taken to read the number of
words in a sentence) is measured in words per
minute.
Serum Carotenoid Analysis
Non-fasting blood samples are collected at each study
visit by standard venepunture techniques in 9 mL
vacuette tubes (BD Vacutainer SST Serum Separation
Tubes, Becton, Dickinson and Company, Plymouth,
United Kingdom) containing a ‘‘Z Serum Sep Clot
Activator.’’ All collection tubes are inverted a min-
imum of five times to ensure appropriate mixing of
the clot activator. The blood samples are allowed to
clot at room temperature for 30 minutes and then
centrifuged for 10 minutes at 2700 rpm in a Gruppe
GC 12 centrifuge (Desaga Sarstedt, Hampshire, UK) to
separate the serum from the whole blood. After
centrifugation, serum is transferred to light-resistant
microtubes and stored at 80 C until the time of
analysis. Carotenoid analysis is carried out using a
procedure described elsewhere.31
Data and Safety Monitoring Committee
An independent data and safety monitoring commit-
tee (DSMC) has been appointed to examine and
review data collected during the CREST project. This
committee scrutinizes the data for evidence of safety
and efficacy each year. The CREST DSMC consists of a
statistician, a medical ophthalmologist, a health sci-
ence researcher and a vision scientist. The DSMC has
full access to the randomization code for both trials
and the authority to break the code if needed. The
DSMC has the authority to recommend any of the
following: continuation of the study uninterrupted,
alteration of either trial or any arm of either trial, or
termination of either trial or any arm of either trial.
DISCUSSION
CREST has been designed to investigate the impact of
supplementation with a combined carotenoid formu-
lation of L, Z and MZ on visual function in normal
subjects (Trial 1) and in subjects with early AMD (Trial
2). Enhancement of visual function as a result of MP
augmentation, if present, is likely the result of its
attenuation of both chromatic aberration and veiling
luminance, with consequential benefits in terms of CS
and glare disability,7 and rests on its anatomical (pre-
receptoral and central retinal)1 and optical (short
wavelength-filtering) properties.2 The hypothesis that
MP confers protection against AMD is premised on
these same attributes of this pigment, as well as its
antioxidant capacity,3,12 as (photo)-oxidative stress is
believed to be important in the pathogenesis of this
condition.60
The landmark AREDS provided level 1 evidence
that supplementation with a formulation of antioxi-
dants and zinc, but which was devoid of the macular
carotenoids, was associated with risk reduction for
visual loss and disease progression in subjects with at
least intermediate AMD.61 The AREDS, therefore,
furnished the scientific community with proof of
principle that supplemental dietary antioxidants are
of benefit in AMD, and somewhat paradoxically,
generated interest in the role that MP might play,
given its exquisite biological relevance to the tissue
affected by this condition. As a consequence, studies
were designed to investigate the putative benefits of
supplementation with MP’s constituent carotenoids
on the course of AMD.
Indeed, the subsequent AREDS2 study which was
recently published, was designed to assess the impact
of supplemental L, Z and omega-3 fatty acids plus
co-antioxidants on progression to advanced AMD in
eyes with at least intermediate AMD.62,63 In brief,
AREDS2 has found that, controlling for baseline AMD
status, none of the treatments were shown to signifi-
cantly reduce risk of AMD progression relative to the
group who received the ‘‘placebo’’ AREDS1 supple-
ment only, although the trend was in favor of the
treatments including L and Z (primary analysis).
Also, there are many important secondary outcome
variables available from this study. For example, there
was a statistically significant (p = 0.01) reduction of 9%
in risk of progression to advanced AMD for subjects
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receiving L and Z when compared with subjects not
receiving L and Z; participants with the lowest dietary
intake of L and Z showed a statistically significant
(p = 0.01) reduction of 26% in risk of progression to
advanced AMD, when compared with subjects not
receiving L and Z; and, there was a statistically
significant (p = 0.02) reduction of 18% in risk of
progression to advanced AMD for subjects receiving
L and Z in the absence of beta carotene when
compared with subjects receiving an AREDS formu-
lation with beta carotene (and not receiving L and Z).
However, it is important to point out the major
differences between CREST and the AREDS (1 and 2)
studies. AREDS was designed and powered to inves-
tigate change in AMD morphology following supple-
mentation with antioxidants, whereas CREST (which
is a much smaller sample) is designed and powered to
investigate change in visual function (i.e. CS) follow-
ing supplementation with the macular carotenoids.
These fundamental differences between two rando-
mized controlled trials need to be appreciated when
either of these studies is under discussion.
Another published clinical trial that deserves men-
tion is the Carotenoids in Age-Related Maculopathy
(CARMA) study. CARMA was a randomized, double-
blind, placebo-controlled clinical trial of L (12 mg) and
Z (0.6 mg) supplementation with co-antioxidants
versus placebo in patients with AMD.64 The primary
outcome measure, corrected distance visual acuity
(CDVA) at one year, did not differ significantly
between the placebo and the intervention arms of
the study.65 It was noted, however, that CDVA was
significantly better in the intervention arm of the
study at 36 months follow-up.18 In addition, an
increase in serum L was associated with significantly
improved CDVA and slowing of progression along
the AMD severity scale.18 However, one clear differ-
ence between CARMA and CREST was the absence of
MZ in the CARMA study intervention, the import-
ance of which has been discussed.
In addition, as a secondary outcome measure, the
impact of macular carotenoid supplementation on
cognitive function is being assessed. Indeed, a recent
study has shown that MP is related to brain caroten-
oid levels,66 and there is a growing body of evidence
that poor antioxidant status represents risk for
age-related loss of cognitive function.67–69 Therefore,
as MP represents a readily accessible and a non-
invasive biomarker of antioxidant status within the
central nervous system (i.e. retina), we believe that it
is important to investigate the relationship, if any,
between MP and cognitive function in CREST.
CREST will ascertain, through sufficiently pow-
ered, double-blind, randomized controlled clinical
trials, the impact of supplementation with all three
macular carotenoids (uniquely including the centrally
dominant macular carotenoid, MZ) on vision in
normal subjects and subjects with AMD. CREST will
inform and advance our understanding of the pro-
tective and optical hypotheses of MP, and potentially
identify ways to optimize vision in the absence of
ocular disease and prevent or delay blindness attrib-
utable to AMD.
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